Medlines cover art

Medlines

Medlines

Written by: Human Content Inc.
Listen for free

Healthcare is changing at breakneck speed, and let's face it, staying informed is getting harder by the day. If only there were a way to get the industry news you need in less time than it takes to get prior auth approved. (Spoiler: There is.) Every Friday, start your day with Dr. Will Flanary (aka Dr. Glaucomflecken), Dr. Alok Patel, Adam Rose, and Eva Johnson as they bring you the week's most important headlines across clinical care, health policy, groundbreaking publications, medical pop culture, and more. Presented with clear, unbiased, fact-first reporting made strictly for healthcare professionals, by healthcare professionals. Prepare to wow your colleagues with how informed you are, all without risking another evening doom-scrolling through 5% actual news and 95% videos of, well, if you know you know. Medicine moves fast... So do we! Learn More: www.medlinespod.com Medlines is A Human Content Production© 2026 Human Content, Inc. and Glaucomflecken, LLC. All rights reserved. Biological Sciences Hygiene & Healthy Living Physical Illness & Disease Politics & Government Science
Episodes
  • Aspirin vs. Blood Thinners, a 9-Year Endo Wait Ends & Cyclospora Hits Taco Bell

    Aspirin vs. Blood Thinners, a 9-Year Endo Wait Ends & Cyclospora Hits Taco Bell
    Jul 17 2026
    Friday, July 17, 2026 In today’s episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) and Adam Rose cover the EPCAT III trial, which found that aspirin alone was non-inferior to an initial course of rivaroxaban followed by aspirin for preventing major blood clots after elective hip or knee replacement in predominantly standard-risk patients. They examine NICE’s draft recommendation allowing two rapid endometriosis tests, EndoSure and Endotest, to enter limited NHS use while researchers gather additional real-world evidence. Plus: They discuss a recall involving more than 2.5 million bottles of prednisolone acetate eye drops, the first HAVANA Act compensation payments, the expanding Cyclospora response, and The Pitt leading the 2026 Emmy nominations with 25 nods. (00:00) Intro (01:07) Aspirin vs. Rivaroxaban After Joint Replacement (03:19) NICE Endorses Rapid Endometriosis Tests (05:30) FDA Recall of Prednisolone Eye Drops (06:07) First Havana Syndrome Payments (06:41) Cyclospora Outbreak Reaches Taco Bell (07:10) The Pitt Leads Emmy Nominations Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today’s Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    11 mins
  • Medicare's $50 GLP-1 Program, an Altered Drug Trial & Cyclospora's 18-State Spread

    Medicare's $50 GLP-1 Program, an Altered Drug Trial & Cyclospora's 18-State Spread
    Jul 10 2026
    Friday, July 10, 2026 In today's episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Eva Johnson cover the retraction of the Advocate trial after FDA reviewers found the avacopan (Tavneos) dataset was unblinded, re-adjudicated, and altered before being relocked, throwing its approval for ANCA-associated vasculitis into doubt. They break down Medicare's new GLP-1 Bridge program, which offers eligible Part D beneficiaries drugs like Wegovy and Zepbound at $50 a month through the end of 2027, and why that copay sits outside normal Part D accounting. They also track a Cyclospora outbreak now reported across 18 states and why routine washing does not reliably kill it. Plus: they also discuss Alibaba's $600 million fentanyl-precursor settlement, the WHO's first emergency-use Ebola (Bundibugyo) diagnostic, France's deadly heat wave, and more. Coverage Timeline: (00:00) Intro(01:04) Vasculitis Trial Retracted:(03:44) Medicare’s GLP‑1 Bridge(06:02) Parasite, Ebola, Heat Wave Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    12 mins
  • ACA Enrollment Collapse, India's Chemo Crisis, & Amy Adams' Canceled CBS Show

    ACA Enrollment Collapse, India's Chemo Crisis, & Amy Adams' Canceled CBS Show
    Jul 3 2026
    Friday, July 3, 2026 In today's inaugural episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Dr. Alok Patel (@alokpatelmd) cover a sharp drop in ACA marketplace enrollment after enhanced tax credits expired, from 24.2 million enrollees in 2025 to roughly 19.2 million in 2026 (a loss of 5 million Americans' health coverage). India is rationing two cornerstone chemotherapy drugs, cisplatin and carboplatin, after supply disruptions tied to rising platinum costs and capped essential medicine prices. A new Annals of Internal Medicine study finds older adults who received a shingles vaccine had a 24 percent lower relative risk of dementia diagnosis. Plus: heat linked to rising suicide rates in young people, the return of the 988 LGBTQ+ crisis line, and a phase 3 trial of infigratinib for achondroplasia. Coverage Timeline: (00:00) Medlines begins! (01:44) ACA enrollment drops as credits expire (03:42) India rations cisplatin & carboplatin (06:03) Shingles vaccine & dementia risk (06:38) Climate, youth suicide & 988 hotline (08:26) Amy Adams' real-life rescue Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production
    Show More Show Less
    13 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet